Exam 2 - Cervical cancer Flashcards
Which populations are most at risk for cervical cancer?
African Americans, hispanics, poor individuals
What is the key preventative measure to prevent cervical cancer?
Early detection because early lesions can be removed
- Take average of 10-12 years (latent period) for HPV to progress to full blown cervical cancer
What are the two main types of cervical cancer, and which type is most common?
- Squamous cell carcinoma (SCC) - most common
- Adenocarcinoma
SCC vs adenocarcinoma - which cell type is found in the ectocervix?
Squamous cell carcinoma (SCC)
SCC vs adenocarcinoma - which cell type is found in the endocervix?
Adenocarcinoma
Which strain of HPV is associated with SCC?
HPV 16
Which strain of HPV is associated with adenocarcinoma?
HPV 18
What tissue type is associted with adenocarcinomas?
Columnar epithelial glandular cells
Cervical cancer risk factors
- Persistent high risk HPV infection that does not clear
- Sexually active at an early age (younger than 18 years)
- Multiple or high risk sexual partners
- Smoking
- Weakened immune system
- COC use for 5+ years
- High parity (3+ full term pregnancies)
- Genetic predisposition
- DES (diethylstilbestrol) exposure
Cervical cancer clinical manifestations
- Mostly asymptomatic in early disease process
- Vaginal discharge
- Abnormal vaginal bleeding (between menses, postcoital, postmenopausal)
- Late symptoms - bladder obstruction, back pain, pelvic pain, leg swelling
Physical exam findings
Should perform pelvic exam, abdominal, inguinal lymph nodes, rectal exam
Cervix appears normal in early disease
- Friable, lesions/growths, hard, immobile, inguinal lymph node swelling
Should women be screened annually for cervical cancer?
No
When should routine screening for cervical cancer begin?
Starting at 21 years through 65 years
- Pap recommended every 3-5 years based on age (conventional slide or liquid based cytology)
- >30 years, include high-risk HPV cotest
Screening recommendations: 21-29 years
- Cytology (pap smears) every 3 years
- Most HPV resolves without intervention
Screening recommendations: ages 30-64 years
Cytology (pap smear) + HPV cotest every 5 years
- Increased detection of CIN 3, adenocarcinoma
- Minimizes number of colposcopies and harm